foxo4-dri vs gdf-11 The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound Structural basis for potency differences

Figure 33 shows the time course of drug accumulation during a constant-rate drug infusion and the time course of drug elimina-tion after stopping an infusion that has reached steady state

Blots were blocked with phosphate-buffered saline with 0.1% Tween 20 and then bound with antibodies for Biotin, after which an enhanced chemiluminescence (ECL) reaction was performed for blot development

Peptide therapy for skin rejuvenation addresses aging at that deeper level by giving cells the signaling molecules they need to behave like younger tissue

The CS-coefficient for bridge strength was 0.517, suggesting moderate stability

It depends on temperature: the higher the temperature, the more soluble the compound will be in water